What GLP-1 biosimilars does Amogen manufacture?

Amogen manufactures semaglutide and liraglutide biosimilar APIs using Saccharomyces cerevisiae recombinant fermentation at Plant 1, Hyderabad. Semaglutide is currently in Phase 1 clinical development targeting Q4 2026 first patient.

What is Amogen Pharma's manufacturing capacity?

Amogen operates 980 Kg total GLP-1 fermentation capacity at Plant 1, Hyderabad — comprising five 15KL fermenters and two 1KL fermenters, making it one of the largest dedicated GLP-1 API facilities in India.

Which markets is Amogen open to partnering in?

Amogen is open to biosimilar API supply and licensing partnerships across India, GCC, ASEAN, Canada, selected Africa and CIS, selected LATAM, European Union and North America.

Why does Amogen use Saccharomyces cerevisiae instead of E. coli?

Amogen's S. cerevisiae expression system mirrors the innovator's host system used by Novo Nordisk, delivering salt-free APIs with correct higher-order structure and solubility at commercial scale above 1000 Kg — advantages that E. coli and synthetic SPPS routes cannot replicate.

What does Amogen provide to biosimilar partners?

Amogen provides drug substance API supply, drug product in pen or cartridge format, analytical packages for DS and DP, ICH-compliant pre-clinical toxicology reports, regulatory and market access support, and long-term volume-linked pricing with secured GLP-1 capacity.

Recombinant peptide and protein biosimilars, built for global supply.

Our innovator-aligned microbial platforms deliver the purity, scale, and regulatory confidence global pharmaceutical partners need.

Partner With Us View Pipeline

Amogen Pharma Plant 1 Hyderabad — India largest recombinant peptide API facility

Partner With Us View Pipeline

WHY AMOGEN?

Precision manufacturing, scaled for global biosimilar supply.

Amogen combines microbial expression expertise, fermentation capacity, and process discipline to advance recombinant biosimilars from development to dependable long-term supply.

Amogen Pharma Plant 1 facility aerial view — Hyderabad recombinant biosimilar manufacturing

75,000L

Total Fermentation Capacity

S. cerevisiae and multi-microbial suites facility

75+

Scientific & Manufacturing Experts

84% in R&D and manufacturing functions, averaging 15 years of peptide expertise.

980+Kgs

Semaglutide API Capacity

Annual recombinant semaglutide manufacturing capacity

Amogen scientist conducting recombinant biosimilar research

10+

Active Development Programs

Across GLP-1 agonists, insulin analogues and immunology

Recombinant peptide and protein biosimilars, built for global supply.

Our innovator-aligned microbial platforms deliver the purity, scale, and regulatory confidence global pharmaceutical partners need.

Partner With Us View Pipeline

WHY AMOGEN?

Precision manufacturing, scaled for global biosimilar supply.

Amogen combines microbial expression expertise, fermentation capacity, and process discipline to advance recombinant biosimilars from development to dependable long-term supply.

75,000L

Total Fermentation Capacity

S. cerevisiae and multi-microbial suites facility

75+

Scientific & Manufacturing Experts

84% in R&D and manufacturing functions, averaging 15 years of peptide expertise.

980+Kgs

Semaglutide API Capacity

Annual recombinant semaglutide manufacturing capacity

10+

Active Development Programs

Across GLP-1 agonists, insulin analogues and immunology

HOW WE BUILD BIOSIMILARS

Proprietary platforms, built to advance high-barrier recombinant biosimilars

Amogen scientist working in recombinant biosimilar research laboratory

01/03

Proprietary Platforms

Proprietary microbial expression systems, led by YESTIDE™
Yeast-based platform engineered for recombinant peptide and protein biosimilars
Spanning GLP-1, insulin, and immunology

HOW WE BUILD BIOSIMILARS

Proprietary platforms, built to advance high-barrier recombinant biosimilars

01/03

Proprietary Platforms

Proprietary microbial expression systems, led by YESTIDE™
Yeast-based platform engineered for recombinant peptide and protein biosimilars
Spanning GLP-1, insulin, and immunology

OUR PIPELINE

A focused pipeline of high-value recombinant biosimilars.

Our growing portfolio of recombinant biosimilar programs across GLP-1, insulin, and immunology spans various stages of development with confirmed FTO in key global markets and structured pathways for licensing and supply.

View Full Pipeline →

Program

DevelopmentAnalytical CMCPre-Clinical

Next Milestone

Semaglutide Biosimilar

Phase 1

Liraglutide Biosimilar

Pre-Clinical

INSULIN ANALOGS

Insulin Degludec Biosimilar

Pre-Clinical

Insulin Aspart Biosimilar

Pre-Clinical

IMMUNOLOGY

Certolizumab Biosimilar

Pre-Clinical

Anakinra Biosimilar

Analytical CMC

View Full Pipeline →

FROM LAB TO COMMERCIAL SUPPLY

One integrated facility for your
recombinant peptide and protein programs.

Whether advancing a peptide through early development or scaling toward commercial supply, Amogen provides the full suite of recombinant manufacturing capabilities under one roof.

Explore our CDMO services →

API MANUFACTURING